AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19995884 — intervention group
Group type: COMPARATOR
Intervention: Attention‐only control condition with education in health dietary practices (NUTRITION)
Number of subjects: 64
Study 18277515 — intervention group
Group type: EXPERIMENTAL
Intervention: Small images (less than 10 degrees)
Number of subjects: 0
Study 18277515 — intervention group
Group type: EXPERIMENTAL
Intervention: Large images (10 degrees or more)
Number of subjects: 0
Study 18277515 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated image generation over 3 consecutive blocks
Number of subjects: 0
Study 15206537 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with bisphosphonates
Number of subjects: 0
Study 15206537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11353457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Home Information Program (CHIP) plus usual care
Number of subjects: 180
Study 11353457 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac discharge information protocol
Number of subjects: 180
Study 9389897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (Mg(OH)2; 411-548 mg Mg/d)
Number of subjects: 33
Study 9389897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8198658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous loading dose of phenytoin
Number of subjects: 28
Study 8198658 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral phenytoin supplementation
Number of subjects: 28
Study 8198658 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous loading dose of phenytoin (entire group analysis)
Number of subjects: 28
Study 3370401 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 20
Study 3370401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29467025 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized BP lowering (10‐15% reduction from admission level)
Number of subjects: 500
Study 29467025 — intervention group
Group type: COMPARATOR
Intervention: Guideline‐recommended BP lowering
Number of subjects: 500
Study 27542303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 μg/kg per h, from ICU admission on the day of surgery until 0800 h on postoperative day 1)
Number of subjects: 700
Study 27542303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous normal saline)
Number of subjects: 700
Study 27542303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 μg/kg per h)
Number of subjects: 700
Study 25690266 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-led telephone triage (GPT)
Number of subjects: 20990
Study 25690266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led computer-supported telephone triage (NT)
Number of subjects: 20990
Study 25690266 — intervention group
Group type: COMPARATOR
Intervention: Overall costs
Number of subjects: 20990
Study 25690266 — intervention group
Group type: COMPARATOR
Intervention: Triage (GPT and NT)
Number of subjects: 20990
Study 24139151 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stretching group
Number of subjects: 56
Study 24139151 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise group followed by a single bout of stretching
Number of subjects: 56
Study 24139151 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise group submitted to repeated bouts of stretching
Number of subjects: 56
Study 24139151 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercised group
Number of subjects: 56
Study 21068687 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week youth baseball conditioning program (3 sessions per week, 75 minutes each)
Number of subjects: 34
Study 21068687 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 18715160 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 followed by PPV23 booster 8 weeks later (primed group)
Number of subjects: 130
Study 18715160 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by standard single dose of PPV23 (unprimed group)
Number of subjects: 130
Study 16377322 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg intravenously
Number of subjects: 270
Study 16377322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 12679174 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/d plant stanol (3.4 g of stanol ester)
Number of subjects: 105
Study 12679174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/d plant stanol (5.1 g of stanol ester)
Number of subjects: 105
Study 12679174 — intervention group
Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 105
Study 11122545 — intervention group
Group type: EXPERIMENTAL
Intervention: Early triage angiography and subsequent therapies based on the angiogram
Number of subjects: 201
Study 11122545 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 201
Study 9169300 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 +/- 2.5 mg/day, 10 +/- 2.5 mg/day, 15 +/- 2.5 mg/day)
Number of subjects: 431
Study 9169300 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 431
Study 9169300 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (15 +/- 5 mg/day)
Number of subjects: 431
Study 1383071 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha therapy
Number of subjects: 122
Study 6092305 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg)
Number of subjects: 12
Study 6092305 — intervention group
Group type: COMPARATOR
Intervention: Naloxone vehicle (control)
Number of subjects: 12
Study 31390464 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-Clinic (integrated chronic care programme)
Number of subjects: 712
Study 31390464 — intervention group
Group type: COMPARATOR
Intervention: Usual care by a cardiologist
Number of subjects: 712
Study 29532078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Teen‐LABS)
Number of subjects: 93
Study 29532078 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (TODAY)
Number of subjects: 93
Study 27002003 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine Group (10 mg bupivacaine 0.5% and 0.5 mg morphine)
Number of subjects: 90
Study 27002003 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-Dex Group (10 mg bupivacaine 0.5%, 0.5 mg morphine and 5 µg dexmedetomidine)
Number of subjects: 90
Study 27002003 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine Group (10 mg bupivacaine 0.5%)
Number of subjects: 90
Study 25298196 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to group therapy
Number of subjects: 272
Study 25298196 — intervention group
Group type: COMPARATOR
Intervention: Referral to individual web-based tobacco treatment
Number of subjects: 272
Study 22252038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SN) mapping with immunohistochemical analysis
Number of subjects: 331
Study 22252038 — intervention group
Group type: COMPARATOR
Intervention: Standard nodal staging
Number of subjects: 331
Study 20357370 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/day for younger girls and 850 mg/day for older girls)
Number of subjects: 85
Study 19338489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (1 g twice daily) in combination with cyclosporine and steroids (impaired group)
Number of subjects: 26
Study 19338489 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal graft function)
Number of subjects: 26
Study 19338489 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with glomerular filtration rate
Number of subjects: 26
Study 15793608 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive LDL-C lowering (high-dose lovastatin therapy)
Number of subjects: 145
Study 15793608 — intervention group
Group type: COMPARATOR
Intervention: Moderate LDL-C lowering (low-dose lovastatin therapy)
Number of subjects: 145
Study 15793608 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 145
Study 15793608 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormally high BMI (BMI > or = 25 kg/m2)
Number of subjects: 145
Study 11875999 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 194
Study 11875999 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 194
Study 10088567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin at 0.043 U/kg per hour
Number of subjects: 10
Study 10088567 — intervention group
Group type: COMPARATOR
Intervention: No intravenous insulin administration
Number of subjects: 10
Study 7738484 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (abstinent from tobacco for 48 h or allowed to smoke freely)
Number of subjects: 22
Study 7738484 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (control group)
Number of subjects: 22
Study 7738484 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 22
Study 1823632 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin therapy (5 mg/m2/day to 700 mg/m2/day in four divided doses)
Number of subjects: 40
Study 1823632 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin therapy
Number of subjects: 40
Study 6367857 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone) for 1 year
Number of subjects: 358
Study 6367857 — intervention group
Group type: COMPARATOR
Intervention: L-PAM (L-phenylalanine mustard) for 2 years
Number of subjects: 358
Study 30514653 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (females)
Number of subjects: 165
Study 30514653 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (males)
Number of subjects: 165
Study 30514653 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (males)
Number of subjects: 165
Study 30514653 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (females)
Number of subjects: 165
Study 30347031 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ECMO
Number of subjects: 249
Study 30347031 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung-protective ventilation
Number of subjects: 249
Study 27075913 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid 600 μg/d
Number of subjects: 20
Study 27075913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24560401 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1005
Study 24560401 — intervention group
Group type: COMPARATOR
Intervention: ANGIO (angiography guidance)
Number of subjects: 1005
Study 22591408 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgical treatment for SAH
Number of subjects: 178
Study 20349685 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole nitrate cream 2%
Number of subjects: 92
Study 16900567 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 0
Study 16900567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16452557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (blood glucose levels normalized to 80 to 110 mg/dL using insulin infusion)
Number of subjects: 1200
Study 16452557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (for patients staying in ICU for three or more days)
Number of subjects: 1200
Study 16452557 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (insulin administered when blood glucose exceeded 215 mg/dL)
Number of subjects: 1200
Study 14998225 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 14998225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0
Study 11232529 — intervention group
Group type: COMPARATOR
Intervention: Capozide-50 (C-50) alone
Number of subjects: 22
Study 11232529 — intervention group
Group type: EXPERIMENTAL
Intervention: Capozide-50 (C-50) + melatonin (3 mg at 10.00 p.m.)
Number of subjects: 22
Study 8737131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200 mg
Number of subjects: 238
Study 8737131 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250 mg
Number of subjects: 238
Study 8737131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 238
Study 1572085 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN-gamma)
Number of subjects: 128
Study 1572085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 4064778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine heparin
Number of subjects: 104
Study 4064778 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine heparin
Number of subjects: 104
Study 31350248 — intervention group
Group type: EXPERIMENTAL
Intervention: STUMBL score (prognostic model)
Number of subjects: 176
Study 29234750 — intervention group
Group type: COMPARATOR
Intervention: Intraoral radiography
Number of subjects: 23
Study 29234750 — intervention group
Group type: COMPARATOR
Intervention: Vertical probing distance (VPD)
Number of subjects: 23
Study 29234750 — intervention group
Group type: COMPARATOR
Intervention: Bone sounding without flap elevation
Number of subjects: 23
Study 25549210 — intervention group
Group type: COMPARATOR
Intervention: Traditional Behavioral Couple Therapy (TBCT)
Number of subjects: 134
Study 25549210 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Behavioral Couple Therapy (IBCT)
Number of subjects: 134
Study 24321569 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric plication (LGP)
Number of subjects: 40
Study 24321569 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic mini-gastric bypass (LMGB)
Number of subjects: 40
Study 21668799 — intervention group
Group type: COMPARATOR
Intervention: Clear fluids at room temperature, 2 h after emergence (C1)
Number of subjects: 237
Study 21668799 — intervention group
Group type: COMPARATOR
Intervention: Clear fluids at body temperature, 2 h after emergence (C2)
Number of subjects: 237
Study 21668799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear fluids at room temperature, 1 h after emergence (E1)
Number of subjects: 237
Study 21668799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear fluids at body temperature, 1 h after emergence (E2)
Number of subjects: 237
Study 18093254 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg kg(‐1) pyrazinamide
Number of subjects: 20
Study 18093254 — intervention group
Group type: COMPARATOR
Intervention: 15 mg kg(‐1) pyrazinamide
Number of subjects: 20
Study 16782182 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced guideline implementation (clinic-level intervention)
Number of subjects: 3509
Study 16782182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart prompt intervention
Number of subjects: 3509
Study 16782182 — intervention group
Group type: COMPARATOR
Intervention: Standard guideline implementation (control)
Number of subjects: 3509
Study 12589392 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)-THC (up to 10 mg)
Number of subjects: 24
Study 12589392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10952732 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenitally deaf individuals
Number of subjects: 2
Study 10952732 — intervention group
Group type: COMPARATOR
Intervention: Normally hearing individuals
Number of subjects: 2
Study 8615355 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (400 IU, n = 10)
Number of subjects: 29
Study 8615355 — intervention group
Group type: EXPERIMENTAL
Intervention: all-rac-alpha-tocopheryl acetate (400 mg, n = 10)
Number of subjects: 29
Study 8615355 — intervention group
Group type: EXPERIMENTAL
Intervention: water-miscible preparation (400 mg, n = 9)
Number of subjects: 29
Study 8615355 — intervention group
Group type: EXPERIMENTAL
Intervention: All preparations (A, B, C)
Number of subjects: 29
Study 8615355 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CF-associated liver disease (n = 8)
Number of subjects: 29
Study 1596385 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine and Tegaderm
Number of subjects: 60
Study 1596385 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine and gauze
Number of subjects: 60
Study 1596385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiclens and Tegaderm
Number of subjects: 60
Study 1596385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiclens and gauze
Number of subjects: 60
Study 6425911 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thioridazine (100 mg THI/day for the first 7 days) and desipramine (200 mg DMI/day for 21 days)
Number of subjects: 14
Study 6425911 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (200 mg DMI/day for 21 days)
Number of subjects: 14
Study 31847898 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of five behavioural and organisational modules tailored to hospital employees.
Number of subjects: 0
Study 31847898 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group receiving the complex intervention after the last follow-up measurement.
Number of subjects: 0
Study 30354838 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique with a local mucosal flap (n=50)
Number of subjects: 100
Study 30354838 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracapsular tonsillectomy (n=50)
Number of subjects: 100
Study 26832647 — intervention group
Group type: EXPERIMENTAL
Intervention: CareCentre
Number of subjects: 29
Study 23978222 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (2.5 to 10 mg three times daily for 2 weeks)
Number of subjects: 20
Study 23978222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23978222 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 20
Study 22325733 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1200 mg
Number of subjects: 54
Study 22325733 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 6000 mg
Number of subjects: 54
Study 22325733 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (active control)
Number of subjects: 54
Study 22325733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19085624 — intervention group
Group type: COMPARATOR
Intervention: Single-dose maternal methadone administration
Number of subjects: 40
Study 19085624 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose maternal methadone administration
Number of subjects: 40
Study 17466338 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine (APO) 4 mg
Number of subjects: 56
Study 17466338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15308893 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolateral external fixation
Number of subjects: 0
Study 15308893 — intervention group
Group type: COMPARATOR
Intervention: Early hip spica casting
Number of subjects: 0
Study 11291581 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments from the Health Education and Research Trial (HEART) Project
Number of subjects: 0
Study 11291581 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education strategies
Number of subjects: 0
Study 11291581 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational change strategies
Number of subjects: 0
Study 9211569 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 72
Study 9211569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8390768 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of alpha lipoic acid daily for 3 months
Number of subjects: 80
Study 8390768 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of selenium (sodium selenite) daily for 3 months
Number of subjects: 80
Study 8390768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IE of D‐alpha‐tocopherol daily for 3 months
Number of subjects: 80
Study 8390768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant treatment)
Number of subjects: 80
Study 3105472 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (5 mg)
Number of subjects: 15
Study 3105472 — intervention group
Group type: EXPERIMENTAL
Intervention: cromoglycate (20 mg)
Number of subjects: 15
Study 3105472 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 15
Study 30946382 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐EX group (extraluminal CT guided group)
Number of subjects: 70
Study 30946382 — intervention group
Group type: COMPARATOR
Intervention: CV‐IN group (conventional intraluminal intubation group)
Number of subjects: 70
Study 30946382 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐EX group
Number of subjects: 70
Study 30946382 — intervention group
Group type: COMPARATOR
Intervention: CV‐IN group
Number of subjects: 70
Study 27236818 — intervention group
Group type: EXPERIMENTAL
Intervention: VMI+ at 40 keV
Number of subjects: 47
Study 27236818 — intervention group
Group type: COMPARATOR
Intervention: VMI at 70 keV
Number of subjects: 47
Study 27236818 — intervention group
Group type: COMPARATOR
Intervention: F_0.5 series
Number of subjects: 47
Study 27236818 — intervention group
Group type: EXPERIMENTAL
Intervention: VMI+ at 40, 50, and 60 keV
Number of subjects: 47
Study 26601565 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Number of subjects: 89
Study 24338893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy (Pravastatin)
Number of subjects: 0
Study 24338893 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22816385 — intervention group
Group type: EXPERIMENTAL
Intervention: Okada Purifying Therapy (OPT)
Number of subjects: 19
Study 22816385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18795300 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiography plus MRI
Number of subjects: 208
Study 18795300 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective MRI
Number of subjects: 208
Study 18795300 — intervention group
Group type: COMPARATOR
Intervention: Radiography only
Number of subjects: 208
Study 17207146 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A
Number of subjects: 60